Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 21, 2026 11:12 ET | Source: Research and Markets

Photoimmunotherapy Market to Surge with 10.64% CAGR, Reaching USD 3.65 Billion by 2031

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Photoimmunotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's...
January 07, 2026 16:00 ET | Source: Immuneering Corporation

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
December 17, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial, Securing Alignment with FDA and EMA
December 16, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
December 09, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

Castle Biosciences announced the publication of an independent expert consensus paper endorsing the Company’s DecisionDx-Melanoma test.
November 27, 2025 08:20 ET | Source: Research and Markets

Her3-Targeted Immunotherapies Pipeline and Competitive Intelligence Report

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of Her3-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
November 25, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
November 14, 2025 07:00 ET | Source: Castle Biosciences, Inc.

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

Castle will present new data showing the clinical value of DecisionDx-Melanoma in improving sentinel lymph node biopsy decision making at Dermato-Onco2025.
October 24, 2025 04:05 ET | Source: Castle Biosciences, Inc.

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Castle is presenting data on DecisionDx®-Melanoma and its pipeline atopic dermatitis (AD) test at the 25th Annual Fall Clinical Dermatology Conference.
October 14, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

New York, USA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight The melanoma market...